Rheumatoid arthritis (RA) is a chronic disease of the joints that can cause a disabling degree of pain and significantly interfere with an individual’s day-to-day living.
Scientists revealed the operational mechanism of possible drug targets for numerous diseases like rheumatoid arthritis, cancer, and even COVID-19.
Tiny synthetic particles known as dendrimers have been shown to avoid detection by our immune system and so could be used to develop a new system to deliver drugs into the body without triggering a reaction.
With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation.
In recent years, scientists have developed monoclonal antibodies -; proteins that mimic the body's own immune defenses -; that can combat a variety of diseases, including some cancers and autoimmune disorders such as Crohn's disease.
NYU Tandon professors Mary Cowman and Jin Ryoun Kim recently published a paper describing a novel peptide with broad therapeutic potential to combat chronic inflammation in multiple diseases.
Researchers created a “nanobody”, a small fragment of a llama antibody, that can evade human cytomegalovirus as it hides away from the immune system.
Researchers used NMR techniques to determine the structure of a nanobody, facilitating a better understanding of how the protein fights against diseases.
Human genetics and genomifefcs contributed $265 billion to the U.S. economy in 2019 and has the potential to drive significant further growth given major new areas of application, according to a new report issued today by the American Society of Human Genetics (ASHG).
A first-of-its-kind genetic database for autoinflammatory and autoimmune disorders has been created by Japanese researchers.
Researchers within the Biomedicine Discovery Institute at Monash University have made a breakthrough in understanding the role played by high-risk immune genes associated with the development of rheumatoid arthritis (RA).
TARM1 is a receptor protein, whose function in the working of the immune system is not known yet. Now, in a new research work, Japanese researchers have analyzed mouse models to investigate the promising role of TARM1 protein in the pathogenesis of rheumatoid arthritis.
Autoimmune diseases, in which the body's own immune system attacks healthy tissue, can be life-threatening and can impact all organs.
Researchers still do not know much about diseases like periodontitis, rheumatoid arthritis, and osteoporosis, which are characterized by bone loss.
According to a research team, headed by Decio L. Eizirik, MD, PhD, a Scientific Director from the Indiana Biosciences Research Institute Diabetes Center, new treatments for autoimmune disorders can be identified by studying both target tissues and the immune system together.
Systemic sclerosis is an autoimmune disease associated with inflammation and fibrosis, or scarring, that affects organs including the skin, heart, kidney and lungs.
A researcher at the University of Tartu described new associations between Neandertal DNA and autoimmune diseases, prostate cancer and type 2 diabetes.
Opened in 2016, Manchester’s Stoller Biomarker Discovery Centre (SBDC) is a globally renowned, multi-million-pound precision medicine research facility.
Effector regulatory T cells, also known as eTreg cells, are a specialized subset of white blood cells that maintain the immune system.
A University of Massachusetts Amherst environmental health scientist has used an unprecedented objective approach to identify which molecular mechanisms in mammals are the most sensitive to chemical exposures.
A group of Moscow scientists has discovered and explained the activity mechanism of a new anti-cancer molecule -- diphenylisoxazole. This molecule has been shown to be effective against human cancer cells. The research, published in the journal Bioorganic & Medicinal Chemistry Letters, makes it possible to produce an affordable cancer treatment drug.